Infirst Healthcare

The company's business model centers on acquiring or licensing known medical products and enhancing them, often by adding natural ingredients, to create more consumer-friendly versions. This approach allows for a faster regulatory path to market. Infirst generates revenue through the sale of its product portfolio to over 70 top-tier retailers in the U.S. and through licensing agreements. The company serves retail and professional channels via a direct and broker selling organization, with logistics managed from its facility in Plainfield, Indiana.

In October 2023, Infirst USA Holdings, LLC, the parent company of Infirst Healthcare Inc., was acquired by Carlin Consumer Health, a business specializing in acquiring OTC brands. Despite the acquisition, Infirst continues to operate as a wholly owned subsidiary. The product portfolio includes several well-known brands marketed under a trademark licensing agreement with McNeil Consumer Pharmaceuticals Co. Key products include Mylanta®, a liquid antacid for heartburn and acid indigestion; Mylicon®, a pediatrician-recommended brand for infant gas relief; and Dr. Cocoa®, a cocoa-flavored cough and cold medicine for children. Additionally, the company distributes Ypsomed Orbit® infusion sets and Clickfine® pen needles.